

Wah Kheong Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6752643/publications.pdf>

Version: 2024-02-01

105
papers

7,662
citations

136940

32
h-index

56717

83
g-index

108
all docs

108
docs citations

108
times ranked

6673
citing authors

#	ARTICLE	IF	CITATIONS
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	3.7	2,171
2	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , 2017, 66, 1022-1030.	3.7	734
3	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020, 14, 889-919.	4.2	422
4	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	8.1	411
5	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 70-85.	2.8	358
6	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
7	Epidemiology of <i>Helicobacter pylori</i> Infection and Public Health Implications. <i>Helicobacter</i> , 2011, 16, 1-9.	3.5	316
8	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	12.1	195
9	A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1940-1949.e8.	4.4	154
10	Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1470-1476.	2.8	148
11	Global multi-stakeholder endorsement of the MAFLD definition. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 388-390.	8.1	135
12	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 185-198.	8.1	130
13	Appointment waiting times and education level influence the quality of bowel preparation in adult patients undergoing colonoscopy. <i>BMC Gastroenterology</i> , 2011, 11, 86.	2.0	118
14	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 86-98.	2.8	117
15	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 2057-2064.	12.1	113
16	Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. <i>Digestive Diseases and Sciences</i> , 2020, 65, 623-631.	2.3	110
17	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	8.1	82
18	Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2570-2580.e37.	4.4	75

#	ARTICLE	IF	CITATIONS
19	Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1396-1403.	2.8	69
20	Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. <i>United European Gastroenterology Journal</i> , 2017, 5, 76-85.	3.8	67
21	Non-alcoholic fatty liver disease in diabetics – prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1375-1383.	2.8	66
22	Asian perspective on NAFLD-associated HCC. <i>Journal of Hepatology</i> , 2022, 76, 726-734.	3.7	59
23	Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region – the GO ASIA initiative. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 816-825.	3.7	54
24	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	4.4	49
25	Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 989-1000.	3.7	47
26	Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications. <i>JGH Open</i> , 2018, 2, 235-241.	1.6	47
27	A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis. <i>Hepatology International</i> , 2015, 9, 594-602.	4.2	46
28	Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1405-1413.	2.8	44
29	Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2013, 7, 65-71.	4.2	40
30	Can the same controlled attenuation parameter cutoffs be used for M and XL probes for diagnosing hepatic steatosis?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1787-1794.	2.8	40
31	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 867-875.	0.4	40
32	Epidemiology of non-alcoholic fatty liver disease in Asia. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 1-8.	1.4	39
33	Nonalcoholic Fatty Liver Disease: A Global Perspective. <i>Clinical Therapeutics</i> , 2021, 43, 473-499.	2.5	38
34	Endoscopic ultrasound-guided tissue acquisition with or without macroscopic on-site evaluation: randomized controlled trial. <i>Endoscopy</i> , 2020, 52, 856-863.	1.8	35
35	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2296-2306.e6.	4.4	35
36	Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2719-2731.	3.9	32

#	ARTICLE	IF	CITATIONS
37	MACK ³ (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 1315-1324.	3.9	31
38	Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 135-141.	2.8	31
39	Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. <i>Metabolism: Clinical and Experimental</i> , 2022, 126, 154911.	3.4	31
40	Genome-Wide Analysis of Copy Number Variation Identifies Candidate Gene Loci Associated with the Progression of Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e95604.	2.5	30
41	Limited Utility of Plasma M30 in Discriminating Non-Alcoholic Steatohepatitis from Steatosis – A Comparison with Routine Biochemical Markers. <i>PLoS ONE</i> , 2014, 9, e105903.	2.5	27
42	Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2018, 12, 44-55.	4.2	27
43	Split-dose vs same-day reduced-volume polyethylene glycol electrolyte lavage solution for morning colonoscopy. <i>World Journal of Gastroenterology</i> , 2014, 20, 14488.	3.3	26
44	Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. <i>BMC Gastroenterology</i> , 2020, 20, 88.	2.0	25
45	Non-alcoholic fatty liver disease in a young multiracial Asian population: a worrying ethnic predilection in Malay and Indian males. <i>Hepatology International</i> , 2014, 8, 121-127.	4.2	23
46	Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 320-325.	2.8	23
47	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2843-2845.e2.	4.4	21
48	Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 795-811.	2.8	21
49	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2017, 12, e0174982.	2.5	20
50	Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 486-498.	8.9	20
51	Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1297-1305.	2.0	19
52	Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 470-480.	3.7	19
53	Epidemiological differences of common liver conditions between Asia and the West. <i>JGH Open</i> , 2020, 4, 332-339.	1.6	18
54	Validation study of the Leeds Dyspepsia Questionnaire in a multi-ethnic Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1669-1676.	2.8	15

#	ARTICLE	IF	CITATIONS
55	Association between non-alcoholic fatty liver disease evaluated by transient elastography with extracranial carotid atherosclerosis in a multiethnic Asian community. <i>JGH Open</i> , 2019, 3, 117-125.	1.6	15
56	Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1804-1812.	2.8	15
57	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. <i>EClinicalMedicine</i> , 2021, 41, 101145.	7.1	14
58	Narrow-band imaging and white-light endoscopy with optical magnification in the diagnosis of dysplasia in Barrett's esophagus: results of the Asia-Pacific Barrett's Consortium. <i>Endoscopy International Open</i> , 2015, 03, E14-E18.	1.8	13
59	Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future. <i>Seminars in Liver Disease</i> , 2020, 40, 331-338.	3.6	13
60	Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 448-458.	8.1	13
61	Liver stiffness measurement in non-alcoholic fatty liver disease: Two is better than one. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1404-1411.	2.8	12
62	Progression of liver disease in non-alcoholic fatty liver disease: A prospective clinicopathological follow-up study. <i>Journal of Digestive Diseases</i> , 2014, 15, 545-552.	1.5	11
63	Ultrasonography-diagnosed non-alcoholic fatty liver disease is not associated with prevalent ischemic heart disease among diabetics in a multiracial Asian hospital clinic population. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 284-291.	1.5	11
64	Endorsing the redefinition of fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 163.	8.1	11
65	Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy. <i>Journal of Digestive Diseases</i> , 2015, 16, 537-540.	1.5	10
66	Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease. <i>PLoS ONE</i> , 2021, 16, e0250300.	2.5	10
67	Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. <i>World Journal of Gastroenterology</i> , 2020, 26, 2416-2426.	3.3	9
68	Meaning of non-overlapping patients between the MAFLD and NAFLD definitions. <i>Liver International</i> , 2022, 42, 271-273.	3.9	9
69	Diagnosis of Fibrosis Using Blood Markers and Logistic Regression in Southeast Asian Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2021, 8, 637652.	2.6	8
70	Evaluation of Patient Satisfaction of an Outpatient Colonoscopy Service in an Asian Tertiary Care Hospital. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-6.	1.5	7
71	Clinical outcomes and direct costings of endoluminal clipping compared to surgery in the management of iatrogenic colonic perforation. <i>Journal of Digestive Diseases</i> , 2013, 14, 670-675.	1.5	7
72	Emerging new standard for non-invasive assessment of liver disease mortality in non-alcoholic fatty liver disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 135-137.	1.5	7

#	ARTICLE	IF	CITATIONS
73	Evaluation of patient satisfaction of an outpatient gastroscopy service in an Asian tertiary care hospital. <i>BMC Gastroenterology</i> , 2012, 12, 96.	2.0	6
74	Copy number variation in exportin-4 (XPO4) gene and its association with histological severity of non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2015, 5, 13306.	3.3	6
75	Quantification of Liver Fat in NAFLD: Available Modalities and Clinical Significance. <i>Current Hepatology Reports</i> , 2019, 18, 492-502.	0.9	6
76	Volumetric Liver Fat Fraction Determines Grade of Steatosis More Accurately Than Controlled Attenuation Parameter in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 945-953.e2.	4.4	5
77	Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1131-1138.	2.8	5
78	Low physical activity and energy dense Malaysian foods are associated with non-alcoholic fatty liver disease in centrally obese but not in non-centrally obese patients with diabetes mellitus. <i>Asia Pacific Journal of Clinical Nutrition</i> , 2015, 24, 289-98.	0.4	5
79	Epidemiological trends of gastrointestinal and liver diseases in Malaysia: A single-center observational study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1732-1740.	2.8	5
80	Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: The STORM-C-1 phase II/III trial. <i>Journal of Hepatology</i> , 2018, 68, S123-S124.	3.7	4
81	Limited applicability of cathepsin D for the diagnosis and monitoring of non-alcoholic steatohepatitis. <i>JGH Open</i> , 2019, 3, 417-424.	1.6	4
82	Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 751-757.	2.8	4
83	Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2022, 28, 1563-1573.	3.3	4
84	A new bile acid treatment for non-alcoholic fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 747-749.	8.1	3
85	Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1429-1430.	3.7	3
86	Calculated parameters for the diagnosis of Wilson disease. <i>Singapore Medical Journal</i> , 2022, , .	0.6	3
87	A pilot study of empagliflozin for the treatment of non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus. <i>Journal of Hepatology</i> , 2018, 68, S110-S111.	3.7	2
88	Use of simple scoring systems for a public health approach in the management of non-alcoholic fatty liver disease patients. <i>JGH Open</i> , 2020, 4, 1155-1161.	1.6	2
89	Cyclosporine rescue therapy in autoimmune liver cirrhosis: A case report. <i>Turkish Journal of Gastroenterology</i> , 2012, 23, 599-603.	1.1	2
90	Commentary: changing aetiology of peptic ulcers. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 291-292.	3.7	1

#	ARTICLE	IF	CITATIONS
91	Oxidized low-density lipoprotein in non-alcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1516-1518.	2.8	1
92	Endoscopic sleeve gastropasty: Case report, technique and literature review. <i>Journal of Digestive Diseases</i> , 2017, 18, 598-603.	1.5	1
93	Impact of hepatic steatosis and controlled attenuation parameter (CAP) on accuracy of fibrosis staging using transient elastography. <i>Journal of Hepatology</i> , 2017, 66, S674-S675.	3.7	1
94	The High Prevalence and Predictors of Advance Fibrosis in Elderly Patients with Liver Biopsy Confirmed Non-Alcoholic Fatty Liver Disease (NAFLD): The Goasia Study. <i>Gastroenterology</i> , 2017, 152, S1199-S1200.	1.3	0
95	Editorial: NAFLD in Asia—clinical associations with advanced disease become clearer. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1037-1038.	3.7	0
96	A non-invasive biomarker of hepatic inflammation based on magnetic resonance imaging. <i>Journal of Hepatology</i> , 2018, 68, S565.	3.7	0
97	Comparison of HepaFat-Scan and controlled attenuation parameter for the estimation of hepatic steatosis in patients with non-alcoholic fatty liver disease using histology as the reference standard. <i>Journal of Hepatology</i> , 2018, 68, S569-S570.	3.7	0
98	Reply to: CHAI and MACK as noninvasive indices for nonalcoholic steatohepatitis. <i>Liver International</i> , 2019, 39, 1588-1588.	3.9	0
99	IDDF2019-ABS-0271—Liver stiffness measurement in non-alcoholic fatty liver disease: two is better than one. , 2019, , .		0
100	Allele HLA-DQB1*06 reduces fibrosis score in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2020, 50, 947-954.	3.4	0
101	Breastfeeding to Prevent NAFLD. <i>Hepatology</i> , 2021, 74, 2939-2941.	7.3	0
102	Endoscopic Management of Colonoscopy-related Perforation. <i>Journal of Digestive Endoscopy</i> , 2018, 09, 047-052.	0.2	0
103	Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. <i>World Journal of Gastroenterology</i> , 2020, 26, 2415-2425.	3.3	0
104	The role of B cells in metabolic (dysfunction)-associated fatty liver disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 0-0.	1.5	0
105	Editorial: metagenome-assembled genomes in non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 755-756.	3.7	0